Search

Search Constraints

You searched for: Author/Creator Lo Re, Giovanni

Search Results

1. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. (February 2016)

2. Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. (February 2016)

3. Clinical validity of a DPYD‐based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Issue 12 (14th July 2015)

4. Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication. Issue 1 (4th January 2023)

5. Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin-2 use in solid tumors: A feasibility off-label experience. (January 2019)

6. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. (November 2015)

7. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients. (November 2015)

8. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. (March 2015)

9. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. (March 2015)

10. Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. (March 2015)